Literature DB >> 9398471

Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice.

E Bezard1, S Dovero, B Bioulac, C Gross.   

Abstract

Although a valuable 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of human Parkinson's disease has been developed, our knowledge of the course of nigral degeneration remains fragmentary. Experimental factors which could possibly influence the destructive process must be taken into account. To evaluate the impact of experimental design, we compared the effects of different schedules of injection of the same cumulative dose of MPTP, in mice, by measuring tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta. Massive injection of the total dose over 1 day (4 injections of 20 mg/kg) destroyed more dopaminergic neurons than did the long-term daily injections of a lower dose of MPTP (20 injections of 4 mg/kg). This suggests that different schedules of administration of MPTP might induce different mechanisms of neuronal death. These mechanisms need to be better understood if chronic models of intoxication that replicate the evolution of human Parkinson's disease more precisely are to be developed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398471     DOI: 10.1006/exnr.1997.6648

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  14 in total

Review 1.  Heterogeneity of dopamine release sites in health and degeneration.

Authors:  Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2019-11-05       Impact factor: 5.996

2.  Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice.

Authors:  Xiaoyang Shan; Liying Chi; Michael Bishop; Chun Luo; Lindsey Lien; Zheng Zhang; Rugao Liu
Journal:  Stem Cells       Date:  2006-01-19       Impact factor: 6.277

3.  Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.

Authors:  Gelareh Alam; Melissa Edler; Shelbie Burchfield; Jason R Richardson
Journal:  Neurotoxicology       Date:  2017-04-01       Impact factor: 4.294

4.  Neuroprotective changes of striatal degeneration-related gene expression by acupuncture in an MPTP mouse model of Parkinsonism: microarray analysis.

Authors:  Yeong-Gon Choi; Sujung Yeo; Yeon-Mi Hong; Sabina Lim
Journal:  Cell Mol Neurobiol       Date:  2010-11-25       Impact factor: 5.046

5.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Authors:  Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer
Journal:  Science       Date:  2017-09-01       Impact factor: 47.728

6.  Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum.

Authors:  C J van der Schyf; K Castagnoli; S Palmer; L Hazelwood; N Castagnoli
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

7.  Localization and expression of group I metabotropic glutamate receptors in the mouse striatum, globus pallidus, and subthalamic nucleus: regulatory effects of MPTP treatment and constitutive Homer deletion.

Authors:  Masaaki Kuwajima; Marlin H Dehoff; Teiichi Furuichi; Paul F Worley; Randy A Hall; Yoland Smith
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

8.  MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations.

Authors:  Charlotte Laloux; Philippe Derambure; Alexandre Kreisler; Elise Houdayer; Servane Bruezière; Régis Bordet; Alain Destée; Christelle Monaca
Journal:  Exp Brain Res       Date:  2008-01-26       Impact factor: 1.972

9.  Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains.

Authors:  Cécile Moro; Napoleon Torres; Nabil El Massri; David Ratel; Daniel M Johnstone; Jonathan Stone; John Mitrofanis; Alim-Louis Benabid
Journal:  BMC Neurosci       Date:  2013-03-27       Impact factor: 3.264

10.  Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease.

Authors:  Isabelle St-Amour; Mélanie Bousquet; Isabelle Paré; Janelle Drouin-Ouellet; Francesca Cicchetti; Renée Bazin; Frédéric Calon
Journal:  J Neuroinflammation       Date:  2012-10-09       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.